Walleye Capital LLC Sells 409,248 Shares of Merit Medical Systems, Inc. $MMSI

Walleye Capital LLC reduced its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 73.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,963 shares of the medical instruments supplier’s stock after selling 409,248 shares during the quarter. Walleye Capital LLC’s holdings in Merit Medical Systems were worth $10,406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of MMSI. Lido Advisors LLC grew its stake in Merit Medical Systems by 3.8% in the 4th quarter. Lido Advisors LLC now owns 3,836 shares of the medical instruments supplier’s stock worth $324,000 after buying an additional 140 shares in the last quarter. AMI Asset Management Corp increased its holdings in shares of Merit Medical Systems by 0.8% in the 1st quarter. AMI Asset Management Corp now owns 21,818 shares of the medical instruments supplier’s stock worth $1,504,000 after buying an additional 168 shares during the last quarter. Maryland State Retirement & Pension System raised its position in shares of Merit Medical Systems by 2.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 8,693 shares of the medical instruments supplier’s stock valued at $766,000 after buying an additional 180 shares in the last quarter. Blue Trust Inc. raised its position in shares of Merit Medical Systems by 11.0% during the 4th quarter. Blue Trust Inc. now owns 1,853 shares of the medical instruments supplier’s stock valued at $163,000 after buying an additional 184 shares in the last quarter. Finally, First Horizon Corp lifted its holdings in shares of Merit Medical Systems by 19.7% during the 4th quarter. First Horizon Corp now owns 1,117 shares of the medical instruments supplier’s stock worth $98,000 after acquiring an additional 184 shares during the last quarter. 99.66% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MMSI has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating on shares of Merit Medical Systems in a research report on Friday, July 10th. Citigroup reaffirmed an “outperform” rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Needham & Company LLC cut their price objective on Merit Medical Systems from $101.00 to $90.00 and set a “buy” rating for the company in a report on Friday, May 1st. Weiss Ratings lowered Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Finally, Compass Point set a $107.00 price objective on Merit Medical Systems in a report on Monday, April 20th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $92.80.

Merit Medical Systems Stock Performance

NASDAQ MMSI opened at $73.11 on Thursday. The company has a 50-day simple moving average of $67.72 and a two-hundred day simple moving average of $72.21. The company has a quick ratio of 3.46, a current ratio of 5.08 and a debt-to-equity ratio of 0.45. Merit Medical Systems, Inc. has a 12-month low of $59.74 and a 12-month high of $94.75. The firm has a market cap of $4.36 billion, a price-to-earnings ratio of 31.65, a PEG ratio of 2.29 and a beta of 0.52.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, topping the consensus estimate of $0.84 by $0.10. The firm had revenue of $381.88 million for the quarter, compared to the consensus estimate of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.86 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. On average, equities analysts forecast that Merit Medical Systems, Inc. will post 3.62 EPS for the current year.

Insider Buying and Selling

In other news, insider Brian G. Lloyd purchased 2,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were acquired at an average price of $62.62 per share, with a total value of $125,240.00. Following the acquisition, the insider directly owned 2,000 shares in the company, valued at approximately $125,240. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the transaction, the director owned 7,809 shares in the company, valued at $488,921.49. The trade was a 39.04% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.70% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.